<DOC>
	<DOCNO>NCT03000530</DOCNO>
	<brief_summary>This two-part ( open-label follow double-blind ) study evaluate safety , tolerability , pharmacokinetics , efficacy SAGE-217 62 subject diagnose moderate severe Major Depressive Disorder .</brief_summary>
	<brief_title>A Study Evaluate SAGE-217 Subjects With Moderate Severe Major Depressive Disorder</brief_title>
	<detailed_description>Part A study open-label design dose SAGE-217 14 day . Part B study randomize , double-blind , parallel-group , placebo-controlled design . Eligible subject randomize SAGE-217 placebo 14 day .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Subject diagnosis Major Depressive Disorder present least 4week period diagnose Structured Clinical Interview DSMIV Axis I Disorders ( SCIDI ) Subject history suicide attempt Subject history treatmentresistant depression , define persistent depressive symptom despite treatment adequate dos antidepressant two different class adequate amount time Active psychosis Medical history seizures Medical history bipolar disorder , schizophrenia , and/or schizoaffective disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Depression</keyword>
</DOC>